HEIDI HOUSTON: Open Payments
NPI 1265180020 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$780 in 37 payments from 12 companies in 2025. Trend: 2023 $1,001 · 2024 $778 · 2025 $780
Food & beverage: $780
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $209 |
| PFIZER INC. | 5 | $113 |
| Xeris Pharmaceuticals, Inc. | 2 | $95 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $88 |
| ABBVIE INC. | 5 | $86 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Abbott Laboratories | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26 |
| Dexcom, Inc. | 1 | $17 |
Products named: KEVEYIS, XIFAXAN, NURTEC ODT, Wegovy, Ozempic, Rybelsus, TRELEGY ELLIPTA, JARDIANCE.
Industry payments across VA — which companies pay providers there.
